Lori Ferrins

Lori Ferrins

Auto-generated profile, based on publicly available information

Lori Ferrins

Department of Pharmaceutical Sciences

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
BSBrian C. Sanders
Brian C. Sanders
SPSuman Pokhrel
Suman Pokhrel
ALAudrey D. Labbe
Audrey D. Labbe
IMIrimpan I. Mathews
Irimpan I. Mathews
CCConnor J. Cooper
Connor J. Cooper
JPJerry M. Parks
Jerry M. Parks
Direct-acting antivirals are needed to combat coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). The papain-like protease (PLpro) domain of Nsp3 from SARS-CoV-2 is essential for viral replication. In addition, PLpro dysregulates the host immune response by cleaving ubiquitin and interferon-stimulated gene 15 protein from host proteins. As a result, PLpro is a promising target for inhibition by small-molecule therapeutics. Here we design a series of covalent inhibitors by introducing a peptidomimetic linker and reactive electrophile onto analogs of the noncovalent PLpro inhibitor GRL0617. The most potent compound inhibits PLpro with kinact/KI = 9,600 M−1 s−1, achieves sub-μM EC50 values against three SARS-CoV-2 variants in mammalian cell lines, and does not inhibit a panel of human deubiquitinases (DUBs) at >30 μM concentrations of inhibitor. An X-ray co-crystal structure of the compound bound to PLpro validates our design strategy and establishes the molecular basis for covalent inhibition and selectivity against structurally similar human DUBs. These findings present an opportunity for further development of covalent PLpro inhibitors.

2 December 2013 in Australian Journal of Chemistry
Verified
Journal Article
Closed access
PDF file
JBJonathan Bayldon Baell
Jonathan Bayldon Baell
LFLori Ferrins
Lori Ferrins
HFHendrik Falk
Hendrik Falk
GNGeorge Nikolakopoulos
George Nikolakopoulos
Pan assay interference compounds (PAINS) are readily discovered in any bioassay and can appear to give selective and optimisable hits. The most common PAINS can be readily recognised by their structure. However, there are compounds that closely resemble PAINS that are not specifically recognised by the PAINS filters. In addition, highly reactive compounds are not encoded for in the PAINS filters because they were excluded from the high-throughput screening (HTS) library used to develop the filters and so were never present to provide indicting data. A compounding complication in the area is that very occasionally a PAINS compound may serve as a viable starting point for progression. Despite such an occasional example, the literature is littered with an overwhelming number of examples of compounds that fail to progress and were probably not optimisable in the first place, nor useful tool compounds. Thus it is with great caution and diligence that compounds possessing a known PAINS core should be progressed through to medicinal chemistry optimisation, if at all, as the chances are very high that the hits will be found to be non-progressable, often after a significant waste of resources.

15 February 2021 in Cell Chemical Biology
Verified
Journal Article
Closed access
JDJayme L. Dahlin
Jayme L. Dahlin
DADouglas S. Auld
Douglas S. Auld
IRIna Rothenaigner
Ina Rothenaigner
SHSteve Haney
Steve Haney
JSJonathan Z. Sexton
Jonathan Z. Sexton
BWBridget Wagner
Bridget Wagner

17 July 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
LFLori Ferrins
Lori Ferrins
MGMichelle Gazdik
Michelle Gazdik
RRRaphaël Rahmani
Raphaël Rahmani
SVSwapna Varghese
Swapna Varghese
Melissa Louise SykesMelissa Louise Sykes
Melissa Louise Sykes
JBJonathan Bayldon Baell
Jonathan Bayldon Baell

9 July 2016 in Metabolomics
Verified
Journal Article
Open access
PDF file
DSDaniel Stoessel
Daniel Stoessel
CNCameron Nowell
Cameron Nowell
AJAmy J. Jones
Amy J. Jones
LFLori Ferrins
Lori Ferrins
KEKatherine M. Ellis
Katherine M. Ellis
DCDarren Creek
Darren Creek
Introduction Trypanosoma brucei is the causative agent of human African trypanosomiasis, which is responsible for thousands of deaths every year. Current therapies are limited and there is an urgent need to develop new drugs. The anti-trypanosomal compound, 3-(oxazolo[4,5-b]pyridine-2-yl)anilide (OXPA), was initially identified in a phenotypic screen and subsequently optimized by structure–activity directed medicinal chemistry. It has been shown to be non-toxic and to be active against a number of trypanosomatid parasites. However, nothing is known about its mechanism of action. Objective Here, we have utilized an untargeted metabolomics approach to investigate the biochemical effects and potential mode of action of this compound in T. brucei. Methods Total metabolite extracts were analysed by HILIC-chromatography coupled to high resolution mass spectrometry. Results Significant accumulation of ceramides was observed in OXPA-treated T. brucei. To further understand drug-induced changes in lipid metabolism, a lipidomics method was developed which enables the measurement of hundreds of lipids with high throughput and precision. The application of this LC–MS based approach to cultured bloodstream-form T. brucei putatively identified over 500 lipids in the parasite including glycerophospholipids, sphingolipids and fatty acyls, and confirmed the OXPA-induced accumulation of ceramides. Labelling with BODIPY-ceramide further confirmed the ceramide accumulation following drug treatment. Conclusion These findings clearly demonstrate perturbation of ceramide metabolism by OXPA and indicate that the sphingolipid pathway is a promising drug target in T. brucei.

19 September 2016 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SRStephanie Russell
Stephanie Russell
RRRaphaël Rahmani
Raphaël Rahmani
AJAmy J. Jones
Amy J. Jones
HNHarriet Newson
Harriet Newson
KNKevin Neilde
Kevin Neilde
MPMatthew J. Piggott
Matthew J. Piggott